Roche Licenses Nurix Therapeutics' Bexobrutideg

Roche has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg, an investigational Bruton's Tyrosine Kinase (BTK) degrader. Roche will pay Nurix Therapeutics an upfront cash payment of over $700 million, with potential development, regulatory, and sales milestones that could bring the total value to $2.3 billion. Development costs will be shared 60% by Roche and 40% by Nurix Therapeutics. The companies will co-commercialize bexobrutideg in the U.S., splitting profits and losses equally, while Roche will handle commercialization outside the U.S., with Nurix Therapeutics receiving royalties. Bexobrutinib is an orally bioavailable, brain-penetrant BTK degrader that eliminates the BTK protein from cells, offering a potential advantage over existing BTK inhibitors by overcoming resistance mechanisms. A Phase III clinical trial for bexobrutideg in second-line CLL is planned for summer 2026. The collaboration expands Roche's hematology portfolio and opens new therapeutic avenues in immunology and neurology.